POU4F2 and neuroblastoma: Since increased Brn-3b in neuroblastoma cells confers resistance to chemotherapeutic drugs such as cisplatin [11], which are commonly used with paclitaxel as first-line chemotherapeutic treatment of ovarian cancers, we were interested in studying Brn-3b expression in ovarian cancer cell lines following treatment with cisplatin and/or paclitaxel.